Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.03 USD | -0.41% | -3.53% | +27.84% |
Financials (USD)
Sales 2024 * | 69.71M | Sales 2025 * | 72.54M | Capitalization | 255M |
---|---|---|---|---|---|
Net income 2024 * | -125M | Net income 2025 * | -117M | EV / Sales 2024 * | 3.66 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.51 x |
P/E ratio 2024 * |
-2.07
x | P/E ratio 2025 * |
-2.41
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.91% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | -0.41% | ||
1 week | -3.53% | ||
Current month | -12.45% | ||
1 month | -2.75% | ||
3 months | -14.38% | ||
6 months | +25.57% | ||
Current year | +27.84% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 12.03 | -0.41% | 60,589 |
24-05-23 | 12.08 | -5.70% | 112,844 |
24-05-22 | 12.81 | +2.73% | 93,346 |
24-05-21 | 12.47 | 0.00% | 118,608 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.84% | 255M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+43.79% | 40.47B | |
-10.87% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ENTA Stock